Overview

Melatonin for Adolescent Migraine Prevention Study

Status:
Terminated
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, multi-site double-blind placebo-controlled trial of melatonin (2 different dosing arms) vs. placebo for migraine prevention in adolescents. We intend to enroll approximately 210 participants over 15 months at two sites: UCLA and UCSF. The duration of participation for each participant will be 4 months.
Phase:
Phase 2
Details
Lead Sponsor:
Amy Gelfand
Collaborator:
University of California, Los Angeles
Treatments:
Melatonin